TruthArchive.ai - Tweets Saved By @Davemuns1361

@newstart_2024 — Camus

Posted - October 6, 2025 at 3:34 PM

Saved - December 13, 2025 at 12:12 AM

reSee.it AI Summary

A discussion reports unusual, long, rubbery clots tied to the COVID-19 spike protein, described as microclots with amyloid-like structure that obstruct vessels. Cited are embalmers, surgeons, and Dr. Raisa Pretorius, who suggests spike protein alone can trigger rapid blood-protein clumping, persisting for months and evading standard clottreatment. The thread debates vaccine design (mRNA vs other) and mentions spike-targeted therapies as a potential approach, framing a persistent risk.

@newstart_2024 - Camus

A disturbing and consistent pattern is emerging from morgues, operating rooms, and laboratories worldwide, pointing to a catastrophic and novel form of clotting linked to the COVID-19 spike protein. Esteemed pathologist Dr. Ryan Cole shares critical findings from frontline medical professionals: 1. The Embalmer's Discovery: "Congealed Clots" Never Seen Before Embalmers are reporting unprecedented "back pressure" during procedures, leading to the extraction of long, rubbery, congealed clots—some measuring inches, even feet in length. Surgeons confirm pulling identical structures from living patients. 2. These Are NOT Normal Clots This isn't standard thrombosis. VAERS data shows thousands of clotting reports across all vaccine brands. The concern is the nature of these clots. - They are often microclots, invisible on standard scans but devastating to circulation. - They are described as "proteinaceous" and "amyloid-like," forming a bizarre, branching structure that blocks entire vascular trees. 3. The Root Cause: A Rogue Spike Protein Groundbreaking research by Dr. Raisa Pretorius in South Africa reveals the mechanism: - The spike protein alone can trigger immediate clumping of blood proteins, bypassing the body's classical clotting cascade. - This explains why these abnormal, dense clots form directly in the bloodstream. 4. Persistent Spike, Persistent Danger The spike protein persists in the body for months, whether from infection or the shot, circulating and creating a chronic, low-grade threat. This continuous presence can repeatedly induce these dangerous clotting pathways. 5. Why Standard Treatments Fail Doctors are finding that typical clot-busting agents (like tPA) are often ineffective. The reason is twofold: - The body's natural clot-dissolving system (plasminogen) may be depleted. - These amyloid-like protein masses are structurally resistant to conventional anti-coagulation therapies. Conclusion & Call to Action: Dr. Cole states unequivocally: We are using a shot designed for an extinct virus (Wuhan strain) that does not prevent infection from current variants (Omicron). The result is a medical paradox: all risk, no benefit. We are inducing severe pathological processes—catastrophic clotting, immune suppression, and cancer-promoting pathways—with a product that is technically "expired" from a medical standpoint. The data is clear. The mechanism is identified. The human cost is mounting. It is time to halt these shots.

Video Transcript AI Summary

Dr. Pretorius and a colleague discuss unusual clotting observed after COVID-19 vaccination, including embalmers reporting back pressure when introducing embalming fluid and the extraction of very long, congealed clots—six inches to several feet—as well as patients with long brachial clots. They note thousands of clotting reports in VAERS across all vaccine types, describing these clots as not normal. Some clots cause major emboli affecting circulation to the lungs, detected by scans and perfusion studies, while others are microclots with a branching pattern visible in imaging. A clinician also shared a photo of a clot with a complete branching pattern into medium and smaller vessels. Dr. Pretorius’ work is cited to explain the mechanism: spike protein can induce immediate clumping of proteins in platelet-poor plasma in the absence of platelets, a highly unusual clotting pathway not relying on the classical coagulation cascade. This is described as a proteinaceous, pseudo-amyloid–like clot. The spike protein is reported to circulate after vaccination, with studies in the Journal of Immunology showing spikes in circulation and exosomes up to four months after shots. Long-haul COVID data (Patterson’s study) reportedly shows S1 protein present in nonclassical monocytes in blood, suggesting persistence of spike protein, whether from infection or the vaccine, which can induce clotting pathways on its own. Dr. Pretorius discusses observations of upregulation of intercellular adhesion molecules (ICAMs) on leukocytes within clots, causing white blood cells to adhere in addition to fibrin, contributing to difficulty in dissolving these clots. Concerning treatment and detection, the speakers describe depletion of plasminogen, reducing the body’s ability to break down clots, and note that standard anticoagulants are less effective against these clots, which are described as amyloid-like and atypical. They emphasize that these are not the classical clotting pathways involving platelet activation and typical thrombin–fibrin cascades. They contrast this with expectations of standard clotting mechanisms and reference the unusual, non-classical pathway highlighted by Pretorius. The discussion also mentions the idea that spike protein in circulation can drive clotting without the usual platelet activation, and that some patients have continued to experience spike-related effects long after vaccination. They assert that vaccines were developed targeting the original Wuhan strain and may not cover Omicron; they suggest the shot’s risk-benefit balance is unfavorable given ongoing clotting, immune suppression, and cancer-inducing pathways, and they claim data indicate those who receive two or three shots may acquire Omicron at a higher rate than those unvaccinated. They conclude that the shot is expired for a virus that is no longer circulating in its original form and argue that vaccination induces dangerous pathologic processes with no protective benefit.

AI Similar Videos

Full Transcript

Speaker 0: Let's talk about clotting. I watched another podcast that you did and you were specifically talking about clot formation and some of the findings of even embalmers who were looking at cadavers after a patient had deceased and they had had the COVID-nineteen shot. What's going on there? Speaker 1: Doctor. Yeah, this is a great question as well. I've been in contact with several, well, pathology colleagues, coroners, and embalmers. And the embalmers, they were noticing that when they would go to put the embalming fluid in, they would get back pressure they'd never seen before. And they started pulling out these long congealed clots. And, you know, six inches long, 12 inches long, four feet long. And I was talking to a surgeon in Florida this week and he had pulled out two several, you know, several foot long clots from a patient. I know several patients who've had, you know, long brachial brachial clots. So, some patients have made it and you know, have their their clots removed But obviously, know we're seeing increased clotting in the VAERS reporting not only from J and J, which was halted for a brief period because of the clots in the venous sinus in the brain, but also you know, these lung clots that we're seeing in their thousands upon thousands of clotting reports in bears for all of the shots. And these these clots are not normal clots. This is the concern on a scan. If you if you are suspecting, say, a big embolus that blocks the circulation that goes to both lungs, you can usually see that on a scan and then you do perfusion studies. A lot of these also end up being micro clots. I had another doctor bring a photo of a clot he had pulled and it had basically the whole branching pattern of the clot going into all the medium and smaller sized vessels as well. It was incredibly impressive. I'll try to get that picture from him so you can post that. But the clots are more of a it's a proteinaceous clot and it's what we call a pseudo amyloid like. And Doctor. Pretorius, she's done some cutting edge studies and understanding. She's in South Africa and Doctor. Erisa Pretorius in her papers has shown that you can take the spike protein in the absence of platelets, put it into platelet poor plasma and cause immediate clumping of the proteins in the absence of this little cascade that we always go through to form a clot. Clotting. Yeah. So that spike protein in and of itself and induces a highly unusual clumping of proteins in our bloodstream. And so this explains, you know, partially why we're seeing some of these outcomes. And so after the shot, we know that spike protein is in circulation. There was a great study in the Journal of Immunology showing the spikes circulating in the body and exosomes up to four months after the shots. And we know even from some of the long haul COVID patients, Doctor. Patterson's study showed that S1 protein present in our nonclassical monocytes in our blood. So we know that spike is persistent, be it from a severe infection and lasting in some of these long haul patients and or from the synthetic sequence producing chronic low grade picogram levels of spike protein that in and of itself can induce these clotting pathways. And so, you know, I have many of them I'm studied. I've studied a handful of my been on the road too much last couple of weeks. Just arrived and just received a shipment of some more to study. So I'm looking at cellular adhesion molecules within the clots. You get a lot of trapped white blood cells as well. And what I'm seeing is an upregulation of these molecules on the surface called ICAMS in intercellular adhesion molecules that are upregulated, causing the white blood cells to stick in addition to these proteins, in addition to the fibrin. Part of the reason clinically why doctors are having difficulty clock busting, you know, with all the different, Speaker 0: like with TDA or, yeah, Speaker 1: it's like or whatever. Yes, yeah, It's will. It's interesting because, you know, normally clots will use plasminogens to break them down to start breaking down those fibrin products. And so those fibrin split products will detect with a D dimer test in the laboratory. But there for one, I think we're depleting some of our plasminogen when these clots are forming. Then two, the standard anti clotting agents aren't working well, breaking down these congealed amyloid like proteins. Speaker 0: Okay, so these are not classical clots. These are not, you know, looking at the spike protein and the interaction with the spike protein and the ACE2 receptor, you know, think we could have anticipated clotting but I expected more from the classical pathway where you would get platelet activation. This sounds like something different. Speaker 1: Doctor. It is. It is. And that's that's where it's really interesting to review Doctor. Pretorius's papers and studies because she shows this atypical clotting pathway without your classical pathway necessarily being induced. And, you know, it's fascinating that we didn't have this before these shots were rolled out. I mean, these could have been anticipated in mammal models. We ended up picking the most thrombogenic aspect of this virus, the most immune suppressing aspect of this virus, the most immune modulating aspect of this virus. And I mean, in my medical opinion, it makes no sense. I mean, the the shot was made for Wuhan, and we're on to Omicron. I ask people two questions. Is Wuhan present in humanity? No. It's extinct. Do the shots cover Omicron? No, they don't. Well, game over. The shots need to stop because of these clotting pathways, immune suppression, cancer inducing pathways. They're all risk with no benefit at this point, and we're seeing in the data that those who get two or three shots are acquiring Omicron at a higher rate than those who didn't get shots. And we're seeing too many of these, adverse outcomes in individuals getting the shot when it's now a shot for a virus that's extinct. Technically, the shot is expired. Right. And we're inducing these dangerous path pathologic processes in the body with something that's not, protective anyway.

@MarkZamoyski - Mark Zamoyski

@newstart_2024 Do the spike protein vaccines (J&J and A-Z) also induce "amyloid" clots, or is this unique to mRNA VAX ? This goes back to Dr. Malone's disclosures about mRNA VAX having untoward coding sequences for amyloid. It would clear up if it was "spike related" or "untoward coding"

@GrandpaSeth2 - S

@MarkZamoyski @newstart_2024 Spike protein from the lab made virus induces the same clots. It's a BSL-3 rated biohazard in the lab, and people are out there acting like it's a cold because symptoms during the acute phase of infection are mild. HIV is a mild cold when you're first infected too...

@Davemuns1361 - Davemuns

@GrandpaSeth2 @MarkZamoyski Then the question remains, how to clear the spike? No one will tell the public (with the exception of FL CCC). IVR discussion is still heavily censored. So I’m assuming thats part of the solution. “Public Health Experts” also go after NAC, raw dairy and eggs.

@MarkZamoyski - Mark Zamoyski

Only way to clear spike is kill all mRNA'd cells producing spike That is also the best way to selectively kill C19 cancers Here is what needs to be done: Cancer biopsies have revealed ongoing production of spike protein (also a carcinogen via P53 pathways) Ongoing spike production means spike snippets are presented on the cell surface by MHC1, which you can now target with spike specific drugs (e.g. antigen specific cytolytic CD-8 T-Cells). You are not targeting the cancer mutation. You are targeting the viral protein (that apparently your own immune system can no longer kill), but doing that also kills the cancer cells. The above in turn screams of the possible need for that same drug as a prophylactic future necessity. If your immune system is no longer capable of killing spike producing cells, this drug would be the the only way to avoid a lifetime of spike related misery.

@Davemuns1361 — Davemuns

Posted - November 9, 2025 at 6:34 AM

Saved - November 11, 2025 at 5:09 AM

@Davemuns1361 - Davemuns

@NoVA_Campaigns A great interview for anyone uninformed about J6: https://t.co/lzQCGQCcQh

@TuckerCarlson - Tucker Carlson

Ep. 15 Former Capitol Police Chief Steven Sund reveals what really happened on January 6th. Our Fox News interview with him never aired, so we invited him back. https://t.co/opDlu4QGlp